FOLFIRI and BVZ April 4, 2005 for 18 weeks

BVZ ×11 to December 2005

Regional laboratory increasing CEA January 2006

Recurrence

Capecitabine February 2006 ×11 days

FOLFOX April 6, 2006 to June 24, 2006

Regional laboratory increasing CEA June 2006

Recurrence

5-FU and leucovorin continuous infusions for 9 weeks

Regional laboratory increasing CEA September 2006

Recurrence

Capecitabine for 9 weeks to October 2006

Regional laboratory increasing CEA October 2006

Recurrence

Irinotecan and leucovorin December 20, 2006 to January 3, 2007

Regional radiology CT January 2, 2007

Recurrence

BC. January 12, 2007 PB, panitumumab, erlotinib, trastuzumab, 5-FU, methotrexate

Regional radiology April 24, 2007

SD

Molecular profiling-negative (blood)

7

Regional hospital April 25, 2000

Adenocarcinoma of the colon, moderately differentiated

Regional radiology PET April 2000

Liver and lung metastases

Sigmoid colectomy

April 21, 2000

5-FU, leucovorin and BVZ June 2000 to January 2001

Regional radiology CT May 25, 2005

Recurrence

5-FU, leucovorin and BVZ April 2005 to September 2006

Regional radiology PET September 1, 2006

Recurrence

Cetuximab October 4, 2006 to December 19, 2006

Regional radiology PET December 11, 2006

Recurrence

BVZ January 16, 2007 to January 30, 2007

BC. February 6, 2007 PB, lapatinib, BVZ, capecitabine

Regional radiology CT June 13, 2007

PD

Molecular profiling-negative (blood)

8

Regional medical center May 6, 2004

Adenocarcinoma of the colon, moderately differentiated

Regional hospital CT/PET April 2007

Nodule in right lower lung, hypermetabolic. Pelvic mass, hypermetabolic with two additional areas of activity.

Rectosigmoid colon resection May 5, 2004

FOLFIRI May 2004 to July 2004

Oxaliplatin and BVZ March 2007 to November 2007

5-FU, leucovorin, cetuximab, BVZ February 2008 to May 2008

Regional radiology PET/CT May 12, 2008

Recurrence

Exploratory laparotomy and resection of pelvic mass May 23, 2008

Regional radiology PET/CT July 1, 2008

Recurrence